These results consistently confirmed former data from our group in homogeneous FMF cohorts, showing significantly increased S100A12 levels according to genotype and questioning the mechanism, why these patients do constantly release S100A12 despite controlled disease under colchicine treatment. This evidence concerns the gene S100A12 and familial Mediterranean fever.